DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20150888

An unusual case of trifluoperazine induced hypoglycemia

Tarun Sharma, Aradhna Sharma, Parveen Kumar Sharma, Dinesh Kansal

Abstract


Hypoglycemia is a serious condition which if not diagnosed and treated urgently may cause irreversible damage to the brain and may be life threatening. There are various causes attributed to hypoglycemia, but drugs are one of the most important one of them. Various drugs are documented to cause hypoglycemia but we present a rare case report of a 52-year-old male patient with schizoaffective disorder on trifluoperazine who presented in emergency department with documented hypoglycemia and this hypoglycemic episode improved when the drug was withdrawn. When WHO causality assessment scale was applied, trifluoperazine was found as the probable cause of the episodes of hypoglycemia. Therefore, this possibility of hypoglycemia should always be kept in mind while prescribing trifluoperazine.


Keywords


Trifluoperazine, Hypoglycemia, Glucose homeostasis

Full Text:

PDF

References


Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc. 2006;13(4):372-7.

Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, et al. Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009;94(3):741-5.

Owens DC. Meet the relatives: a reintroduction to the clinical pharmacology of “typical” antipsychotics. Adv Psychiatric Treat. 2012;18:323-36.

Osman M, Edwards D, Kilduff M. Trifluoperazine induced angioedema. Case Rep Psychiatry. 2014;Article ID 140329:3. Available at http://www.hindawi.com/journals/crips/2014/140329. Accessed 30 June 2015.

WHO. The use of the WHO-UMC system for standardized case causality assessment. Available at http://www.who-umc.org/Graphics/24734.pdf. Accessed 30 June 2015.

Yang C, Watson RT, Elmendorf JS, Sacks DB, Pessin JE. Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes. Mol Endocrinol. 2000;14(2):317-26.

Yasuda H, Suzuki S, Sawada S, Kanasawa Y, Yamaguchi K, Kume S, et al. Stimulative effects of TMB-8 and trifluoperazine on pancreatic hormone release. Diabetes Res Clin Pract. 1989;6(3):227-32.

Sharifi V, Amini S, Ghaeli P, Saeedinia A. Trifluoperazine-induced cholestatic jaundice. Iran J Psychiatry. 2010;5(3):117-8.